Trial Profile
A Phase 4, Open-Label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Feb 2018
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Autoimmune disorders; Hepatitis C
- Focus Therapeutic Use
- 01 Mar 2016 New trial record